HIV Archives

News and Trends 11 Mar 2019

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Two phase III trials conducted by ViiV Healthcare have concluded that a monthly injection of two anti-HIV drugs is as effective as the standard daily treatment taken by people infected with HIV. The results showed that, after 11 months, the monthly treatment achieved virus suppression levels of over 90% and similar to those of conventional […]

March 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Mar 2019

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […]

March 6, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Jan 2019

Austrian Biopharma Reaches First HIV Vaccine Milestone

Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop an HIV vaccine using the Austrian company’s arenavirus-based technology. Hookipa’s lead candidate is a prophylactic vaccine for cytomegalovirus, a common infection that can be dangerous in people with weak immune systems, such as those with […]

January 3, 2019 - 2 minutesmins - By Helen Albert

Best in Biotech 31 Dec 2018

European Biotech’s Biggest News of 2018

With this year coming to a close, it’s now time to look back at the biggest biotech news stories of 2018 in Europe, which include CRISPR-Cas9 controversy, big financial deals, and spider silk airplanes. The year 2018 brought a lot of change to the biotech industry in Europe, with clinical trials, approvals and Brexit […]

December 31, 2018 - 12 minutesmins - By Jonathan Smith

News and Trends 21 Dec 2018

French Scientists Find a Weak Spot in HIV-Infected Cells

Researchers at the Institut Pasteur were able to selectively kill the cells where HIV hides from antiretroviral drugs, opening the way for a new form of HIV treatments. The reason why HIV comes back when a person stops taking antiretroviral therapy is that it remains hidden and undetected within immune T cells. In a study […]

December 21, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Nov 2018

Potential HIV Treatment Shows Early Stage Promise

According to Phase I/IIa trial results from an Israeli biotech, an HIV drug reduced patients’ HIV levels by up to 99%, and might one day become a new treatment for the infection. The trial, run by Zion Medical, found that the synthetic peptide drug reduced the level of viral RNA in patients’ blood by up to […]

November 6, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2018

Forget Daily Pills: HIV Could Be Treated With Monthly Injections

A monthly antiviral injection may be as good as daily HIV drugs for suppressing infections, reports the British biotech ViiV Healthcare. This could make the treatment of HIV easier for patients and improve compliance. In the first five months of a Phase IIb trial, the company gave 274 HIV-infected adults three daily oral antiretrovirals. After […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

Aelix Therapeutics Gilead Functional HIV Cure

News and Trends 19 Oct 2018

Spanish Biotech Partners Gilead to Develop Functional HIV Cure

AELIX Therapeutics and Gilead will run a clinical trial testing a combination of treatments that has potential to let HIV-infected people ditch lifelong therapy. The trial, which will run in Spain, is planned to start in early 2019 and will recruit around 90 patients in the early stages of HIV infection. After receiving the […]

October 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Aug 2018

London Biotech Gets Positive Phase III Results for its Monthly HIV Treatment

ViiV Healthcare has shown its monthly two-drug HIV treatment works as well as a daily three-drug treatment, which could help reduce the total number of drugs taken by patients. In a Phase III trial that recruited 618 people, London biotech ViiV Healthcare aimed to see if adult HIV-positive patients who had been taking daily antiretroviral […]

August 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 30 Jul 2018

This Transgenic Rice Could Prevent HIV Infections

Researchers in Spain have created a strain of genetically-engineered rice that could provide a cheap alternative to produce medicines for HIV prevention. The risk of HIV infections can be significantly reduced with oral medication. However, pricing is a big issue for people living in impoverished or developing countries who are at risk. Researchers at the […]

July 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Jul 2018

Two Drugs as Good as Three for Treating HIV

ViiV Healthcare reports promising data from two HIV treatments with two drugs instead of the usual three, which have the potential to reduce the side effects of antiretroviral therapy in the long term. People infected with HIV are treated with lifelong antiretroviral therapy, which traditionally consists of three or more different drugs. The British […]

July 25, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jul 2018

UK Biotech to Launch Rapid, Accurate HIV Test in Europe

UK-biotech Owen Mumford plans to launch an HIV diagnostic test in Europe that can produce an accurate result within 15 minutes. Current rapid diagnostic tests for HIV can lead to misdiagnosis, for example when steps in the procedure are not followed in the right order, or too little blood is drawn. The new test, called […]

July 23, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us